- CA$19.91m
- CA$20.18m
- CA$16.48m
- 90
- 63
- 50
- 77
Annual income statement for NexgenRx, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.6 | 11.8 | 12.8 | 13.8 | 16.5 |
| Cost of Revenue | |||||
| Gross Profit | 9.2 | 9.81 | 10.2 | 10.8 | 13.1 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 8.76 | 9.83 | 12.6 | 14.2 | 15.4 |
| Operating Profit | 1.81 | 2.01 | 0.134 | -0.305 | 1.03 |
| Net Income Before Taxes | 1.81 | 2.01 | 0.134 | -0.305 | 1.03 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2.12 | 4.02 | -0.022 | -0.332 | 0.615 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 2.12 | 4.02 | -0.022 | -0.332 | 0.615 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2.12 | 4.02 | -0.022 | -0.332 | 0.615 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.026 | 0.054 | -0 | -0.005 | 0.009 |
| Dividends per Share |